Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
stress urinary incontinence
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "stress urinary incontinence" in MCE Product Catalog:
Cat. No.: HY-171048
CAS No.: 928122-40-1
Target:
Research Areas:
GTx-027 is an orally active and non-steroidal selective androgen receptor modulator (SARM). GTx-027 shows androgen receptor (AR) transactivation effects with the EC50 of 1.8 nM. GTx-027 acts selectively increase muscle weight (anabolic) without affecting secondary sexual organs (androgenic). GTx-027 has the protential for the study of breast cancer and stress urinary incontinence (SUI) .
Cat. No.: HY-14790
CAS No.: 98819-76-2
Synonyms: (S,S)-(+)-Reboxetine
Target:
Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine transporter (NET) inhibitor, with a pIC50 of 9.6 and a pKi of 9.2 in rats, and it can cross the blood-brain barrier. Esreboxetine increases urethral closure pressure and urethral resistance in rats. Esreboxetine is applicable to research related to inflammatory pain and stress urinary incontinence .
Cat. No.: HY-W039283
CAS No.: 345-24-4
Target:
Research Areas:
MCH-1 antagonist 2 (l-BROMO-2,4-DIFLUORO-5-NITROBEN-ZENE) is a melanin concentrating hormone-1 (MCH1) receptor-selective 4-aryl piperidine. MCH-1 antagonist 2 can be used for the research of depression, anxiety, obesity, urge incontinence, urinary incontinence, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, urinary frequency, urinary urgency, nocturia, enuresis, bulimia, bulimia nervosa, anorexia nervosa, major depressive disorder, dysthymic disorder, bipolar 1 and 2 disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, overactive bladder .
Cat. No.: HY-119103
CAS No.: 1065110-62-4
Target:
Research Areas:
PF-03246799 is a potent and selective 5-HT2C receptor agonist with an EC50 of 190 nM and a Ki of 160 nM. PF-03246799 shows selectivity for 5-HT2C over 5-HT2A and 5-HT2B receptors. PF-03246799 has the potential for stress urinary incontinence (SUI) research .
Cat. No.: HY-124947
CAS No.: 1065109-28-5
Target:
Research Areas:
PF-4522654 is a potent, selective and brain-permeable 5-HT2C receptor agonist with an EC50 of 16 nM and a Ki of 8 nM. PF-4522654 shows no measurable functional agonism at no 5-HT2A and 5-HT2B receptors. PF-4522654 can be used for the study of stress urinary incontinence (SUI) .
Cat. No.: HY-119262
CAS No.: 258526-74-8
Target:
Research Areas:
ABT-866 is an α1A-adrenoceptor agonist and an antagonist at the α1B- and α1D-adrenoceptor subtypes. ABT-866 has an EC50 of 0.60 μM for the α1A in the rabbit urethra. ABT-866 has a pA2 value of 5.4 for the α1B in the rat spleen. ABT-866 has a pA2 value of 6.2 for the α1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence .
Cat. No.: HY-W1058741
CAS No.: 945389-41-3
Target:
Research Areas:
α1A Adrenoceptor agonist-1 (compound 13) is an α1A adrenoceptor (α1A adrenoceptor) agonist with an EC50 of 385 nM for α1A. α1A Adrenoceptor agonist-1 exhibits in vitro functional agonistic activity targeting adrenoceptors. α1A Adrenoceptor agonist-1 can be used for the research of stress urinary incontinence .
Cat. No.: HY-137055
CAS No.: 1171824-96-6
PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
Cat. No.: HY-14790A
CAS No.: 635724-55-9
Synonyms: PNU-165442G; (S,S)-Reboxetine succinate
Target:
Research Areas:
Esreboxetine succinate (PNU-165442G; (S,S)-Reboxetine succinate) is a selective norepinephrine transporter (NET) inhibitor, with a pIC50 of 9.6 and a pKi of 9.2 in rats, and it can cross the blood-brain barrier. Esreboxetine succinate increases urethral closure pressure and urethral resistance in rats. Esreboxetine succinate is applicable to research related to inflammatory pain and stress urinary incontinence .
Cat. No.: HY-167227S
CAS No.: 1449371-87-2
Target:
Research Areas:
TAS-303 is an orally effective selective norepinephrine transporter (NET) inhibitor. TAS-303 inhibits human NET ligand binding with a Ki of 50.9 nM, and suppresses NET-mediated norepinephrine uptake with an IC50 of 38.9 nM. TAS-303 enhances norepinephrine-induced contraction in isolated rat urethral tissues, elevates plasma norepinephrine levels in rats, and increases urethral baseline pressure and leak point pressure. TAS-303 is applicable for research related to stress urinary incontinence, norepinephrine reuptake, and lower urinary tract function .
Cat. No.: HY-119103B
CAS No.: 1613666-08-2
Target:
Research Areas:
PF-03246799 monohydrochloride is a potent and selective 5-HT2C receptor agonist with an EC50 of 190 nM and a Ki of 160 nM. PF-03246799 monohydrochloride shows selectivity for 5-HT2C over 5-HT2A and 5-HT2B receptors. PF-03246799 monohydrochloride has the potential for stress urinary incontinence (SUI) research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
